Generation of allo-restricted peptide-specific T cells using RNA-pulsed dendritic cells

References

• Riddell SR, Berger C, Murata M, Randolph S, Warren EH. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. Blood Rev 2003; 17:153 - 62; http://dx.doi.org/10.1016/S0268-960X(03)00007-9; PMID: 12818225
   PubMed Web of Science ®Google Scholar
• Wölfel C, Lennerz V, Lindemann E, Hess G, Derigs HG, Huber C, et al. Dissection and molecular analysis of alloreactive CD8+ T cell responses in allogeneic haematopoietic stem cell transplantation. Cancer Immunol Immunother 2008; 57:849 - 57; http://dx.doi.org/10.1007/s00262-007-0421-1; PMID: 18004563
   PubMed Web of Science ®Google Scholar
• Nishida T, Hudecek M, Kostic A, Bleakley M, Warren EH, Maloney D, et al. Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. Clin Cancer Res 2009; 15:4759 - 68; http://dx.doi.org/10.1158/1078-0432.CCR-09-0199; PMID: 19567591
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103:767 - 76; http://dx.doi.org/10.1182/blood-2003-02-0342; PMID: 12958064
   PubMed Web of Science ®Google Scholar
• Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008; 112:4371 - 83; http://dx.doi.org/10.1182/blood-2008-03-077974; PMID: 19029455
   PubMed Web of Science ®Google Scholar
• Jäger D, Jager E, Knuth A. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol 2001; 54:669 - 74; http://dx.doi.org/10.1136/jcp.54.9.669; PMID: 11533070
   PubMed Web of Science ®Google Scholar
• De Visser KE, Schumacher TN, Kruisbeek AM. CD8+ T cell tolerance and cancer immunotherapy. J Immunother 2003; 26:1 - 11; http://dx.doi.org/10.1097/00002371-200301000-00001; PMID: 12514424
   PubMed Web of Science ®Google Scholar
• Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114:535 - 46; http://dx.doi.org/10.1182/blood-2009-03-211714; PMID: 19451549
   PubMed Web of Science ®Google Scholar
• Offringa R. Antigen choice in adoptive T-cell therapy of cancer. Curr Opin Immunol 2009; 21:190 - 9; http://dx.doi.org/10.1016/j.coi.2009.02.006; PMID: 19297140
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323 - 37; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737; PMID: 19723653
   PubMed Web of Science ®Google Scholar
• Walker LS, Abbas AK. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol 2002; 2:11 - 9; http://dx.doi.org/10.1038/nri701; PMID: 11908514
   PubMed Web of Science ®Google Scholar
• Morris E, Hart D, Gao L, Tsallios A, Xue SA, Stauss H. Generation of tumor-specific T-cell therapies. Blood Rev 2006; 20:61 - 9; http://dx.doi.org/10.1016/j.blre.2005.05.001; PMID: 15978709
   PubMed Web of Science ®Google Scholar
• Savage P, Gao L, Vento K, Cowburn P, Man S, Steven N, et al. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 2004; 103:4613 - 5; http://dx.doi.org/10.1182/blood-2003-11-3903; PMID: 14988155
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245 - 52; http://dx.doi.org/10.1038/32588; PMID: 9521319
   PubMed Web of Science ®Google Scholar
• Javorovic M, Pohla H, Frankenberger B, Wolfel T, Schendel DJ. RNA transfer by electroporation into mature dendritic cells leading to reactivation of effector-memory cytotoxic T lymphocytes: a quantitative analysis. Mol Ther 2005; 12:734 - 43; http://dx.doi.org/10.1016/j.ymthe.2005.03.034; PMID: 15921959
   PubMed Web of Science ®Google Scholar
• Javorovic M, Wilde S, Zobywalski A, Noessner E, Lennerz V, Wolfel T, et al. Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells. J Immunother 2008; 31:52 - 62; http://dx.doi.org/10.1097/CJI.0b013e31815a1202; PMID: 18157012
   PubMed Web of Science ®Google Scholar
• Milani V, Frankenberger B, Heinz O, Brandl A, Ruhland S, Issels RD, et al. Melanoma-associated antigen tyrosinase but not Melan-A/MART-1 expression and presentation dissociate during the heat shock response. Int Immunol 2005; 17:257 - 68; http://dx.doi.org/10.1093/intimm/dxh203; PMID: 15642953
   PubMed Web of Science ®Google Scholar
• Visseren MJ, van Elsas A, van der Voort EI, Ressing ME, Kast WM, Schrier PI, et al. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol 1995; 154:3991 - 8; PMID: 7706738
   PubMed Web of Science ®Google Scholar
• Ho WY, Nguyen HN, Wolfl M, Kuball J, Greenberg PD. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naive repertoire. J Immunol Methods 2006; 310:40 - 52; http://dx.doi.org/10.1016/j.jim.2005.11.023; PMID: 16469329
   PubMed Web of Science ®Google Scholar
• Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 1999; 162:2227 - 34; PMID: 9973498
   PubMed Web of Science ®Google Scholar
• Palermo B, Garbelli S, Mantovani S, Scoccia E, Da Prada GA, Bernabei P, et al. Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo. Eur J Immunol 2005; 35:3153 - 62; http://dx.doi.org/10.1002/eji.200535110; PMID: 16224813
   PubMed Web of Science ®Google Scholar
• Leisegang M, Turqueti-Neves A, Engels B, Blankenstein T, Schendel DJ, Uckert W, et al. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy. Clin Cancer Res 2010; 16:2333 - 43; http://dx.doi.org/10.1158/1078-0432.CCR-09-2897; PMID: 20371691
   PubMed Web of Science ®Google Scholar
• Wilde S, Sommermeyer D, Frankenberger B, Schiemann M, Milosevic S, Spranger S, et al. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Blood 2009; 114:2131 - 9; http://dx.doi.org/10.1182/blood-2009-03-209387; PMID: 19587379
   PubMed Web of Science ®Google Scholar
• Becker C, Pohla H, Frankenberger B, Schuler T, Assenmacher M, Schendel DJ, et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med 2001; 7:1159 - 62; http://dx.doi.org/10.1038/nm1001-1159; PMID: 11590442
   PubMed Web of Science ®Google Scholar
• Nair SK, Hull S, Coleman D, Gilboa E, Lyerly HK, Morse MA. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int J Cancer 1999; 82:121 - 4; http://dx.doi.org/10.1002/(SICI)1097-0215(19990702)82:1<121::AID-IJC20>3.0.CO;2-X; PMID: 10360830
   PubMed Web of Science ®Google Scholar
• Wölfl M, Schalk S, Hellmich M, Huster KM, Busch DH, Berthold F. Quantitation of MHC tetramer-positive cells from whole blood: evaluation of a single-platform, six-parameter flow cytometric method. Cytometry A 2004; 57:120 - 30; http://dx.doi.org/10.1002/cyto.a.10116; PMID: 14750134
   PubMed Web of Science ®Google Scholar
• Schuster IG, Busch DH, Eppinger E, Kremmer E, Milosevic S, Hennard C, et al. Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies. Blood 2007; 110:2931 - 9; http://dx.doi.org/10.1182/blood-2006-11-058750; PMID: 17626842
   PubMed Web of Science ®Google Scholar